CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Bendamustine, Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02689986
NCT02689986Phase 2Completed
CompareCT.gov

The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy

Helse Fonna·interventional·Posted Feb 24, 2016·Updated Jan 9, 2017

In Brief

A Phase 2 clinical trial evaluating Bendamustine, Rituximab for Cold Agglutinin Disease and Autoimmune Hemolytic Anemia. Completed, enrolled 43 participants across 8 sites in 3 countries.

Detailed Summary

Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCold Agglutinin Disease, Autoimmune Hemolytic Anemia
CountriesDenmark, Finland, Norway
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 24, 2016
Enrollment StartJan 1, 2013
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.4 years ago

Interventions

Bendamustine, Rituximabdrug

Bendamustine, Rituximab